Markers of renal disease and function are associated with systemic inflammation in HIV infection

HIV Medicine

Volumn 16, Issue 10, 2015, Pages 591-598

  Gupta, S K ^a   Kitch, D ^b   Tierney, C ^b   Melbourne, K ^c   Ha, B ^d   Mccomsey, G A ^e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c GILEAD SCIENCES   (United States)

^d VIIV HEALTHCARE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Albuminuria; HIV 1; Inflammation; Nephropathy; Proteinuria

Indexed keywords

ALBUMIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CREATININE; CYSTATIN C; INTERLEUKIN 6; PROTEIN; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR I; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR II; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA; AUTACOID; BIOLOGICAL MARKER;

ADULT; ALBUMINURIA; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CREATININE URINE LEVEL; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL SYSTEM PARAMETERS; SECONDARY ANALYSIS; TREATMENT DURATION; URINE ALBUMIN CREATININE RATIO; URINE PROTEIN CREATININE RATIO; BLOOD; COMPLICATION; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; URINE; YOUNG ADULT;

ADULT; BIOMARKERS; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY DISEASES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; YOUNG ADULT;

EID: 84945450441     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12268     Document Type: Article

References (38)

1. Gupta SK, Ong'or WO, Shen C, Musick B, Goldman M, Wools-Kaloustian K. Reduced renal function is associated with progression to AIDS but not with overall mortality in HIV-infected Kenyan adults not initially requiring combination antiretroviral therapy. J Int AIDS Soc 2011; 14: 31.
2. Szczech LA, Hoover DR, Feldman JG etal. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206.
3. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24: 387-394.
4. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 2010; 121: 651-658.
5. Choi A, Scherzer R, Bacchetti P etal. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56: 872-882.
6. Wyatt CM, Hoover DR, Shi Q etal. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010; 55: 73-77.
7. Estrella MM, Parekh RS, Abraham A etal. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010; 55: 217-220.
8. Gupta SK, Komarow L, Gulick RM etal. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. J Infect Dis 2009; 200: 614-618.
9. Hunt PW, Martin JN, Sinclair E etal. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
10. Giorgi JV, Hultin LE, McKeating JA etal. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
11. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
12. Shlipak MG, Matsushita K, Arnlov J etal. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932-943.
13. Driver TH, Scherzer R, Peralta CA etal. Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. AIDS 2013; 27: 2291-2299.
14. Longenecker CT, Fitch D, Sax P, Daar E, Tienery C, McComsey G Atazanavir and tenofovir attenuate the benefit of antiretroviral therapy on cystatin C: ACTG A5224 Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2014.
15. Inker LA, Schmid CH, Tighiouart H etal. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
16. Sax PE, Tierney C, Collier AC etal. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230-2240.
17. McComsey GA, Kitch D, Daar ES etal. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012; 26: 1371-1385.
18. Wyatt CM, Kitch D, Gupta SK etal. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/ emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 2014; 67: 36-44.
19. Gupta SK, Kitch D, Tierney C etal. Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial. Open Forum Infectious Diseases. 2014; 1.
20. Hileman CO, Carman TL, Storer N, Harrill Labbato D, White C, McComsey G. Omega-3 fatty acids do not improve endothelial function in virologically-suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses 2012; 28: 649-655.
21. Wyatt CM, Hoover DR, Shi Q etal. Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy. Antivir Ther 2011; 16: 591-596.
22. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis 2012; 60: 539-547.
23. Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 2009; 14: 543-549.
24. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
25. Gupta SK, Shen C, Mather KJ, Agarwal R, Dube MP. Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension. J Infect Dis 2011; 204: 1946-1950.
26. Campbell L, Dew T, Salota R etal. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol 2012; 13: 85.
27. Labarga P, Barreiro P, Martin-Carbonero L etal. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
28. Kimmel PL, Umana WO, Bosch JP. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol 1993; 39: 17-21.
29. Post FA, Moyle GJ, Stellbrink HJ etal. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55: 49-57.
30. Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
31. Ross AC, Rizk N, O'Riordan MA etal. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49: 1119-1127.
32. Longenecker CT, Hileman CO, Funderburg NT, McComsey G. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis 2014; 59: 1148-1156.
33. Odden MC, Scherzer R, Bacchetti P etal. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007; 167: 2213-2219.
34. Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-infected patients: promising but not yet ready for prime time. Nephrol Dial Transplant 2012; 27: 1305-1313.
35. Inker LA, Wyatt C, Creamer R etal. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61: 302-309.
36. Kalayjian RC, Lau B, Mechekano RN etal. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26: 1907-1915.
37. Goodman SN. Multiple comparisons, explained. Am J Epidemiol 1998; 147: 807-812, discussion 15.
38. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43-46.